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Abstract
The Epstein–Barr virus (EBV) is linked to various B-cell lymphomas, including Burkitt lymphoma (BL), classical Hodgkin
lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) at frequencies ranging, by routine techniques, from 5 to 10%
of cases in DLBCL to >95% in endemic BL. Using higher-sensitivity methods, we recently detected EBV traces in a few
EBV-negative BL cases, possibly suggesting a “hit-and-run” mechanism. Here, we used routine and higher-sensitivity
methods (qPCR and ddPCR for conserved EBV genomic regions and miRNAs on microdissected tumor cells; EBNA1
mRNA In situ detection by RNAscope) to assess EBV infection in a larger lymphoma cohort [19 BL, 34 DLBCL, 44 cHL,
50 follicular lymphomas (FL), 10 T-lymphoblastic lymphomas (T-LL), 20 hairy cell leukemias (HCL), 10 mantle cell
lymphomas (MCL)], as well as in several lymphoma cell lines (9 cHL and 6 BL). qPCR, ddPCR, and RNAscope
consistently documented the presence of multiple EBV nucleic acids in rare tumor cells of several cases EBV-negative by
conventional methods that all belonged to lymphoma entities clearly related to EBV (BL, 6/9 cases; cHL, 16/32 cases;
DLBCL, 11/30 cases), in contrast to fewer cases (3/47 cases) of FL (where the role of EBV is more elusive) and no cases (0/
40) of control lymphomas unrelated to EBV (HCL, T-LL, MCL). Similarly, we revealed traces of EBV infection in 4/5 BL
and 6/7 HL cell lines otherwise conventionally classified as EBV negative. Interestingly, additional EBV-positive cases
(1 DLBCL, 2 cHL) relapsed as EBV-negative by routine methods while showing EBNA1 expression in rare tumor cells by
RNAscope. The relapse specimens were clonally identical to their onset biopsies, indicating that the lymphoma clone can
largely loose the EBV genome over time but traces of EBV infection are still detectable by high-sensitivity methods. We
suggest EBV may contribute to lymphoma pathogenesis more widely than currently acknowledged.
Introduction
About 10–20% of cancers are caused by infectious agents,
ranging from 10% of the total number of cancer cases in the
most developed parts of western countries and up to 20% in
developing countries [1]. Epstein–Barr virus (EBV) is a gam-
maherpesvirus linked to a number of lymphoid and epithelial
malignancies, including Burkitt lymphoma (BL), diffuse large
B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), pri-
mary effusion lymphoma (PEL), various types of T/NK-cell
lymphomas as well as gastric and nasopharyngeal carcinoma
(NPC) [2]. Although the vast majority (>90%) of the world
population exhibits antibodies to EBV, the frequency of the
virus in EBV-associated tumors is highly variable [3, 4]. EBV
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is peerless in its ability to turn a normal B lymphocyte with a
defined life span into an indefinitely growing immortalized cell.
Indeed, after active infection, the virus remains in a latent form
in memory B cells that provide the main cellular reservoir of
the virus [5, 6]. In addition to a restricted set of viral proteins
expressed during latent EBV infection, the virus may impact on
host cell homeostasis by interfering with cellular miRNAs
expression and by encoding its own miRNAs [7–9]. However,
the exact mechanisms by which EBV contributes to lymphoid
malignancies are not well known. The role of the virus is
further confounded by the fact that, within each EBV-
associated cancer, viral infection of tumor cells is docu-
mented by routine methods in only a fraction of cases [10–12].
In this regard, a “hit-and-run” hypothesis has been proposed.
According to this idea, EBV can mediate cellular transforma-
tion through an initial “hit” determined by the viral gene
expression program. After heritable changes have been induced
by the virus in the cellular gene expression and/or after somatic
mutations have been acquired in cellular oncogenes/tumor-
suppressor genes, the virus genome may not be strictly
necessary for tumor maintenance. Then, the virus may be
progressively lost from the lymphoma clone (“run”) after each
cell cycle, because of the known imperfect duplication and
asymmetric partitioning of EBV episomes during S-phase and
M-phase respectively [13, 14]. However, so far little data exist
to support such hypothesis and routine methods to detect the
virus, like immunohistochemistry (IHC) for the viral protein
LMP1 and In situ hybridization (ISH) for EBV-encoded RNAs
(EBER), may have suboptimal sensitivity [15, 16]. Viral gene
and microRNA (miRNA) detection by RT-qPCR in micro-
dissected tumor cells and In situ RNAscope analysis (that
enables RNA detection with single-molecule sensitivity in tis-
sues) have been shown to be sensitive and specific tools for
pathogens detection [17, 18]. Recently, by applying some of
these techniques we were able to document the presence of
EBV nucleic acids at low levels in a limited number (n= 6/6)
of EBER-negative BL cases [19].
Therefore, the aim of the present study was to analyse a
larger case series of lymphoma entities, some with an estab-
lished link to EBV (BL, DLBCL, HL, and follicular lym-
phoma—FL [20, 21]) and some not (T-lymphoblastic
lymphomas (T-LL), hairy cell leukemias (HCL) and mantle
cell lymphomas (MCL) by using quantitative PCR and dro-
plets digital PCR (ddPCR) measurement of EBV genes and
micro-RNAs in purified neoplastic cells along with highly
sensitive RNAscope ISH assay for EBNA1 mRNA, in addi-
tion to routine techniques such as immunohistochemistry for
LMP1 and EBER-ISH on whole-tissue sections. While IHC
for LMP1 and EBER-ISH identified a proportion of EBV-
positive tumors overlapping that reported in the literature in
BL, DLBCL, FL, and HL, measurement of viral gene load, as
well as of viral microRNA and mRNA expression, identified
traces of EBV exposure also in occasional tumor cells of
samples negative by conventional tools. Since in B cells and
epithelial cells EBV epigenetically silences tumor-suppressor
genes including MGMT and CDH1, and since EBV infection
in epithelial cancers correlates with promoter hypermethyla-
tion of these two genes [22–26], we also analysed the
methylation status of such gene promoters in our lymphoma
cases. We found that the methylation status of both genes was
quite similar in conventional EBV-positive cases and in cases
classified as EBV-negative by routine methods but showing
traces of EBV infection; in contrast, cases without any foot-
print of exposure to EBV showed a low level of methylation.
Collectively, our findings provide support to the “hit-




The cases cohort was represented by 148 formalin-fixed and
paraffin-embedded (FFPE) samples, retrieved by the
Archives of Siena University Hospital, as well as by 19
frozen cHL cases (previously studied for other purposes
[27] and 20 fresh HCL cases collected at the Institute of
Haematology in Perugia, which were characterized by
clinical data, morphology, immunophenotype, cytogenetic
and molecular biology consistent with the last World Health
Organization criteria for diagnosis [28]. Specifically, we
analysed 19 BL, 34 DLBCL, 50 FL, 44 cHL (27 nodular
sclerosis, 13 mixed cellularity, 3 lymphocyte-rich, and 1
lymphocyte-depleted), 20 HCL, 10 T-LL, and 10 MCL.
Cell lines
DNA from six BL cell lines (one EBV-positive: Namalwa;
five EBV-negative: Ramos, DG75, BL41, BL2; Akata-2A8),
nine cHL cell lines (seven EBV-negative: SUP-HD1, L540,
HDLM2, L428, KMH2, L1236, UH-01; two EBV-positive:
L591, AM-HLH) and, as controls, two multiple myeloma cell
lines (CAG, RPMI) and five acute meloid leukemia cell lines
(OCI-AML-3, U-937, KG-1, Kasumi-1, TF-1), was isolated
by using Macherey Nagel kit, following manufacturer’s
instructions. The amount and quality of DNA were evaluated
by measuring the optical density (OD) at 260 nm, the 260/230
and the 260/280 ratios using a Nanodrop spectrophotometer
(NanoDrop Technologies LLT, USA).
Immunohistochemistry and EBER-ISH
Immunohistochemical stainings were performed on all FFPE
cases by an automated staining system (Ventana BenchMark
ULTRA, Roche diagnostic, Monza-Italy) with appropriate
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positive and negative controls included in each staining run,
as previously described [29, 30]. We used antibodies against
EBNA1 (Santa Cruz, Heidelberg, 1EB12) and LMP-1
(Abcam, D24G). ISH for EBER was carried out in each
sample on 5 μm-thick section as previously described [29]. A
control slide prepared from a paraffin-embedded tissue block
containing EBV-positive metastatic nasopharyngeal carci-
noma in a lymph node accompanied each hybridization run.
Laser capture microdissection (LCM)
The neoplastic population of each non-Hodgkin lymphoma
sample (including those positive at EBER-ISH) was
microdissected from EBER-ISH stained 3 μM-thick FFPE
sections. Multiple areas, each one containing ~40–50 cells,
were harvested to collect a total number of ~200,000 cells,
using a PixCell II laser capture microdissector (Arcturus
Engineering, MGW, Florence, Italy). The EBER-staining
allowed, in cases with EBER-negative lymphoma cells, to
exclude from microdissection even a single EBER-positive
small reactive lymphocyte that might impact on the fol-
lowing qPCR analyses. Regarding microdissection of cHL
samples, single Hodgkin and Reed/Sternberg (HRS) cells
were individually picked (300–500 cells per case from
Siena; ~1200–1800 cells per case from Perugia) from 5 µM-
thick haematoxylin-eosin stained FFPE sections as descri-
bed above (for cases from Siena) or from 8 μM-thick hae-
matoxylin/eosin-stained frozen sections as described by
Tiacci et al. [27] (for cases from Perugia).
HCL cells were isolated to a purity of ≥95% from
patients’ peripheral blood or bone marrow aspirate after red
blood cell lysis followed by MACS sorting with CD19-
microbeads (Miltenyi Biotec, Bergisch Gladbach, Ger-
many), as previously described [32].
DNA extraction and processing before PCR
Regarding non-Hodgkin lymphoma cases, the micro-
dissected cells were adhered to a CapSure cap with adhesive
transfer film (Arcturus, MWG-Biotech) and then collected
into one standard microcentrifuge tube for the DNA
extraction by using PicoPure DNA extraction kit Arcturus
(Milan, Italy). Regarding FFPE cHL cases from Siena,
DNA from 300 to 600 microdissected cells was extracted by
the QIAmp DNA Mini Kit (Qiagen Ltd, Crawley, UK) and
then subjected to whole-genome amplification (WGA)
using the GenomePlex WGA2 kit (Sigma-Aldrich). The
amplified DNA (ranging from 2 to 5 mg) was purified using
the GenElute PCR clean-up kit (SigmaAldrich) for sub-
sequent PCR amplification. Regarding frozen cHL cases
from Perugia, DNA had been extracted and subjected to
duplicate WGA as previously described [27]. Full details
are given in the Supplementary Materials.
Quantitative PCR and droplets digital PCR assays to
measure EBV Genome Load
All cases were firstly subjected to qPCR assays (Life
Technologies Italia, Italy) targeting the BamHI-W and
EBNA1 conserved regions of the EBV genome. BamHI-W
is a reiterated sequence present at approximately ten copies
per EBV genome and it appears to be the most sensitive
method to prove the presence of the viral genome, whereas
EBNA1 targets a single-copy highly conserved gene
essential for maintaining the virus long-term in dividing
cells. Human Beta globin (HBB) gene was used as refer-
ence cellular gene for normalization of the input DNA.
According to previous literature [31], a standard curve was
generated using tenfold dilutions of Namalwa cell line
DNA containing between 500,000 and 0.5 copies of EBV
DNA, assuming that diploid Namalwa cell line cells carry
two EBV genomes per cell and that each cell contains 6.6
pg of DNA, equivalent to 3.0303 × 105 copies of EBV/μg
DNA. Amplification reactions were performed in technical
triplicates from 100 ng of test DNA. Each experiment
included DNA samples from EBER-positive and EBER-
negative cases, as well as water-only controls. Further
technical details regarding qPCR and quantification of viral
load are given in the Supplementary Materials. Besides
technical negative (water) controls for the PCR amplifica-
tion, as biological negative controls we used 10 samples of
T- LL, 20 samples of HCL [32, 33], and 10 samples of
MCL, as none of these lymphoma entities have ever been
associated to EBV.
Moreover, we independently quantified the absolute
copy numbers of EBNA1 and BamHI-W with droplets
digital PCR (ddPCR; Biorad) using the same primers and
probes, according to the manufacturer’s instructions.
Briefly, the PCR reaction was performed using 100 to 150
ng of DNA, 1 × ddPCR Supermix for Probes (BioRad,
Hercules, CA, USA), 0.30 µM of each primer, and 0.6 µM
of the probe in a total volume of 22 µL. After droplet
generation using QX200TM Droplet Generator instrument
(BioRad), the generated microdroplets were put into a 96-
well plate for amplification. Cycling conditions included
preheating at 95 °C for 10 min followed by 40 cycles of
denaturation at 94 °C for 30 s, annealing at 58 °C for 60 s,
and final heating at 98 °C for 10 min. Then, the PCR plate
was transferred to a QX100 droplet reader (BioRad), and
fluorescence amplitude data were obtained by QuantaSoft
software (BioRad). The absolute copy number of each viral
assays was calculated by Bio-Rad software and showed
as number of copies/µl. This was converted to absolute copy
number per 10,000 cells using the HBB absolute copy
number/µl and assuming a diploid status for this control
cellular gene [34]. More detailed on steps for ddPCR are
given in Supplementary Materials.
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Quantitative reverse transcription-PCR assay to
measure Viral miRNAs
To quantify the expression of three EBV-encoded miRNAs
(EBV-miR-BART9–5p, EBV-miR- BART10-3p, and EBV-
miR-BART19-3p), total RNA was extracted from tumor
cells microdissected from FFPE lymphoma tissue sections
stained for EBER-ISH as described in the previous para-
graph on DNA qPCR, with some modifications to preserve
RNA (Supplementary Materials). Total RNA (ranging from
160 to 230) ng was extracted from approximately 50,000
non-Hodgkin lymphoma cells and 10 ng of RNA per reac-
tion were reverse transcribed by using TaqMan primers
against three EBV-encoded miRNAs, namely EBV-miR-
BART9-5p, EBV-miR-BART10-3p, and EBV-miR-
BART19-3p (TaqMan assays Cat. # 006884, 004421_mat,
197235_mat) in three separate reactions as described [19].
Then, TaqMan probes specific for each selected viral
miRNA were added to analyse by qPCR all cases in tech-
nical triplicates. The small cellular RNA RNU6B was used
as endogenous control (Applied Biosystems, Applera, Italy)
and the expression of each viral miRNAs was calculated
using the 2−Δct formula applied to the replicates’ mean.
Kruskal–Wallis Test was applied for statistical analysis.
In addition, ddPCR was performed to quantify the
absolute copy number of these 3 viral miRNAs, using the
same primers and probes as in qPCR [19]. The protocol
applied was as follows: 100 ng of RNA, 1 × ddPCR
Supermix for Probes (BioRad, Hercules, CA, USA), 2 µl of
each primer, and 1 µl of probe in a total volume of 22 µL.
20 µl of each sample were loaded onto middle wells of a
cartridges for droplet generation and then transferred into a
96-Well Semi-Skirted PCR plate for amplification. Cycling
conditions included preheating at 95 °C for 10 min followed
by 40 cycles of denaturation at 94 °C for 30 s, annealing at
58 °C for 60 s, and final heating at 98 °C for 10 min. The
absolute copy number of each viral assays was calculated
by Bio-Rad software and showed as number of copies/µl.
Then, the total number of copies per ddPCR reaction was
normalized by that of the housekeeping loading control
(RNU6B), and expressed in each case as number of viral
miRNA copies/10,000 RNU6B copies as well as percentage
of the corresponding average value across conventional
EBV-positive cases of the same histology. Full details are
given in the Supplementary Materials.
RNAscope for EBNA1 mRNA
RNAscope is an amplified ISH assay more sensitive than
standard ISH for EBV-encoded RNAs to detect viral gene
expression. It employs a multiple probe pair design strategy in
which two independent probes within each pair (double
Z probes) have to hybridize to the target sequence in tandem
next to each other for signal amplification to occur, which
improves the signal-to-noise ratio. Signal amplification is
achieved by a cascade of hybridization of a nucleic acid pre-
amplifier followed by multiple amplifiers that serve as a
substrate for the subsequent binding of chromogenic mole-
cules to the numerous binding sites in each amplifier [18].
RNA In situ hybridization was performed on FFPE tissue
sections or on fixed cytospins of cell lines using the
RNAscope 2.0 HD Red Chromogenic Reagent Kit
(Advanced Cell Diagnostics, CA) and V-EBV-EBNA1
(Advanced Cell Diagnostic, CA) target probe, according to
the manufacturer’s instructions. Each sample was quality-
controlled for RNA integrity with a probe specific to the
housekeeping PPIB mRNA used as positive control.
Hybridization signals were visualized by chromogenic
reactions using FastRed. Background staining was eval-
uated using a negative control probe specific for bacterial
dihydrodipicolinate reductase (dapB); all lymphoma cases
analysed did not show any dots for the dapB in any cells.
Further technical details are given in the Supplementary
Materials.
Methylation studies
Genomic DNA was extracted from five 5-µm-thick whole
sections of FFPE non-Hodgkin lymphoma sections using
the NucleoSpin Tissue extraction kit (Macherey-Nagel,
Germany) according to the manufacturer’s instructions. The
amount and quality of DNA were evaluated by measuring
the optical density (OD) at 260 nm, the 260/230 and the
260/280 ratios using a Nanodrop spectrophotometer
(NanoDrop Technologies LLT, USA). 300 ng of DNA from
each sample were used for bisulfite conversion, in which
unmethylated cytosine was converted to uracil with the
EpiTect Fast DNA bisulfite kit (Qiagen, Hilden, Germany,
59824) according to the manufacturer’s instructions.
Human HCT116 DKO Non-methylated and Methylated
DNA (Zymo Research, USA, D5014-1/2) were used as
standards controls. Full details of bisulfite conversion and
subsequent PCR are given in the Supplementary Materials.
Results
Findings at conventional immunohistochemistry
and In situ hybridization (ISH)
We screened all lymphoma cases for EBV infection by
performing standard EBER-ISH. For BL we used 9 EBER-
positive cases analyzed in previous papers [17, 19] as
positive controls showing the typical nuclear positivity
staining for EBNA1 as well as EBER-ISH positivity in
almost all neoplastic cells. In addition, we newly collected
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ten sporadic BL cases for which the EBV status was
unknown; of these, only one case was positive at EBER-
ISH and immunohistochemistry for EBNA1, while nine BL
cases were negative for EBNA1 and EBER. In DLBCL
samples, 4 of 34 (12%) samples were positive for EBNA
and LMP-1 by immunohistochemistry and for EBER at
ISH, whereas the remainder were negative for all three
markers. Twelve of 44 (27%) cHL cases were positive for
LMP1A and EBER (mixed cellularity, n= 5; nodular
sclerosis, n= 6; lymphocyte-rich, n= 1), which were both
negative in the other 32 cases. Three of 50 (6%) FL cases
were positive for EBER, in keeping with the rare presence
of EBV infection in FL [20]. Thus, routine methods
detected EBV infection at the expected frequency in our
cohort of EBV- associated lymphomas, whereas control
lymphomas T-LL (n= 10) and MCL (n= 10) were nega-
tive at EBER-ISH also as expected.
Viral genome load by qPCR and droplet digital PCR
in primary lymphoma cells
Quantification by real-time PCR of the EBV genome load in
lymphoma cells microdissected from each case (Supple-
mentary Table 1) was extrapolated from the EBNA1 and
BamHI-W calibration curves derived from Namalwa cells,
where the linear relationship (R2) reached 0.99 for both
genes between the respective Ct value and the log10 value of
the initial EBV genome copy number (Fig. 1). As expected,
qPCR analysis of the 10 EBER-positive BL cases revealed
high viral loads in all of them (Fig. 1 and Supplementary
Table 1), with an average of 829,744 copies/10,000 cells
(ranging from 138,526 to 3,366,413) for EBNA1, and
651,698 copies/10,000 cells (range 122,596–1,991,875) for
BamHI-W. High loads of these two genes were docu-
mented, as expected, also in EBER-positive cases of
DLBCL (n= 4; average of 389,775 EBNA1 copies and
294,316 BamHI-W copies per 10,000 cells), cHL (n= 12;
average of 51,944 EBNA1 copies and 32,648 BamHI-W
copies per 10,000 cells) and FL (n= 3; average of 16,679
EBNA1 copies, and 13,854 BamHI-W copies for 10,000
cells). Conversely, and again as expected, the two viral
genes were always undetected in all water controls and in
all technical triplicates of DNA samples from EBV-
unrelated neoplasms (HCL, n= 20 cases; T-LL, n= 10
cases, MCL, n= 10 cases). Interestingly, however, both
EBV genes were consistently detected in all technical tri-
plicates of 6/9 EBER-negative BL cases (67%; Fisher’s
exact test p value < 0.00001 versus 0/40 HCL, T-LL and
MCL cases), at low copy numbers ranging between 21 and
210 copies/10,000 cells for EBNA1 and 12–150 copies/
10,000 cells for BamHI-W (Fig. 1 and Supplementary
Table 1), confirming and extending our previous results in
other BL cases [19].
Similarly, 11/30 EBER-negative DLBCL cases were also
positive in all technical triplicates (37% of cases, Fisher’s
exact test p value < 0.0001 versus 0/40 HCL, T-LL, and
MCL cases), again at low copy numbers (0–232 EBNA1
copies and 2–95 BamHI-W copies per 10,000 cells; a single
Fig. 1 Detection of EBV genome in lymphoma cases by real-time
quantitative PCR. Serial dilution of Namalwa DNA containing
500,000 to 0.5 copies of EBV genomes were amplified using primer/
probe combinations specific for EBV EBNA1 (a) and BamHI-W
conserved region (b) and the related standard curve was used to
quantify the two genes segments in lymphoma cases of the indicated
histology. The y-intercept corresponds to Ct values while the x-
intercept corresponds to the copy number of each target expressed in
log 10 scale.
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case was negative for EBNA1 but positive for five BamHI-
W copies/10,000 cells). In the remaining DLBCL cases
(19/30), neither EBV gene was detected in any technical
triplicates (Fig. 1 and Supplementary Table 1).
In cHL, one or both EBV genes were again detected at
low levels in all technical triplicates of 16/32 EBER-
negative samples (50%, Fisher’s exact test p value < 0.0001
versus 0/40 HCL, T-LL, and MCL cases) with copy num-
bers per 10,000 cells ranging from 0 to 475 for EBNA1 and
from 4 to 315 for BamHI-W (6 cases resulted qPCR-
positive for BamHI-W, but not for EBNA1) (Fig. 1 and
Supplementary Table 1). cHL cases positive at qPCR were
present both in the series from Siena (n= 11/16 cases) and
in that from Perugia (n= 5/16 cases), and included
various histologies (nodular sclerosing, n= 12; mixed cel-
lularity, n= 3; lymphocyte-rich, n= 1). Finally, also 3/47
EBER-negative FL cases proved positive in all technical
triplicates (6% of cases—Fisher’s exact test p value 0.24
versus 0/40 HCL, T-LL and MCL cases), with an average of
4–17 EBNA1 copies and 6–8 BamHI-W copies per 10,000
cells (Fig. 1 and Supplementary Table 1). Neither EBV
gene was detected in any technical triplicates of the
remaining EBER-negative cHL cases (16/32) and FL cases
(44/47).
Thus, we observed consistent presence of EBV genes, at
levels widely varying within a low range, in conventionally
EBER-negative BL, DLBCL, cHL, and FL cases at notable
frequencies (67%, 37%, 50%, and 6%, respectively).
To further confirm these findings and independently
measure the absolute copy numbers of EBNA1 and BamHI-
W, all EBER-negative samples that resulted qPCR-positive
were also analyzed by ddPCR. While both genes were
detected at high levels in EBER-positive B-cell lymphoma
cases (Supplementary Table 1), ddPCR confirmed the low-
level presence of one or both viral genes in all EBER-
negative/qPCR-positive samples tested (6/6 BL; 11/11
DLBCL; 16/16 cHL; 3/3 FL), with copy numbers ranging
from 1 to 207 copies for BamHI-W/10,000 cells and 0,24 to
302 copies for EBNA1/10,000 cells. Conversely, neither
EBV gene was detected in any EBER-negative/qPCR-
negative lymphomas studied (3BL, 5 DLBCL, 5 cHL, 5 FL;
Supplementary Table 1).
Viral genome load in BL and HL cell lines by droplet
digital PCR
Although the above data were obtained from EBER-
negative primary lymphoma cells purified through micro-
dissection, we wanted to further rule out any possible
contribution of contaminating reactive cells to the qPCR/
ddPCR signal observed in microdissected tumor cells. To
this end, we subjected to ddPCR for the EBNA1 and
BamHI-W genes several established cell lines of cHL origin
(n= 9; 7 EBV-negative; two EBV-positive) and BL origin
(five EBV-negative; one EBV-positive), using two multiple
myeloma and five acute meloid leukemia cell lines as
negative controls. As expected, EBV-positive BL and cHL
cell lines showed a high copy number in both viral assays
(Supplementary Fig. 1). On the other hand, one or both viral
genes were detected at low level in 6/7 EBV-negative HL
cell lines (copy number ranging between 1.3 and 11.4
copies/10,000 cells for BamHI-W and 0.3–2.6/10,000 cells
for EBNA1) and 4/5 EBV-negative BL cell lines (copy
number ranging between 0.4 and 2.8 copies/10,000 cells for
BamHI-W and 0.11–1.7/10,000 cells for EBNA1). Con-
versely, neither EBV gene was detected in any cell lines
used as negative controls (Supplementary Fig. 1).
In situ detection of EBNA1 mRNA expression
To provide an In situ validation of the above findings, we
checked EBNA1 mRNA expression by sensitive RNAscope
that, by preserving the morphological context, allowed us to
identify the morphological nature of cells contributing to the
positive qPCR/ddPCR signals. We analyzed 32 and 20
EBER-negative cases that respectively did or did not show a
signal at DNA qPCR for EBNA1 (Supplementary Table 1).
The characteristic red punctuate nuclear staining pattern of
such assay was observed, usually as a single dot and
occasionally during mitotic division, in scattered rare cells
of morphologically clear tumor origin in most EBER-
negative/EBNA1-qPCR-positive lymphoma cases tested
(6/9 BL, 8/10 DLBCL, 7/10 cHL, 2/3 FL), but in no tumor
cells of any EBER- negative/EBNA1-qPCR-negative cases
(2 BL, 5 DLBCL, 8 cHL, 5 FL) (Fig. 2; Supplementary
Table 1) that were instead positive for the control PPIB
mRNA probe (not shown). The lymphoma cases with tumor
cells positive for EBNA1 at the DNA level by qPCR but not
at the RNA level by RNAscope (i.e., 3/6 BL, 2/10 DLBCL,
3/10 cHL, 1/3 FL) were consistently those with the lowest
EBNA1 gene load at DNA qPCR within each lymphoma
entity (Supplementary Table 1). Conversely, in all EBER-
positive lymphoma cases tested (10/10 BL, 4/4 DLBCL, 12/
12 cHL, and 3/3 FL) most neoplastic cells were stained as
expected, and they often showed multiple red dots per
nucleus (Fig. 2 and Supplementary Table 1), indicating a
higher viral genome load per cell. Negative controls (10 T-
LL and 10 MCL cases) did not show any signal regarding
EBNA1, while showing positivity for the control gene, as
expected (not shown). Similarly, RNAscope analysis of
cultured cHL cells cytospun on glass slides revealed mul-
tiple EBNA1 red dots in most cells of conventional EBV-
positive lines and a single dot in rare cells of all 4 con-
ventional EBV-negative lines that showed traces of EBNA1
infection on ddPCR; conversely, not a single EBNA1 dot
was observed in any cells of a conventional EBV-cell line
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(KMH2) that showed a ddPCR signal for BamHI-W but not
for EBNA1, attesting to the high specificity of the RNA-
scope assay (Fig. 3).
Thus, we confirmed the presence of EBV genes and their
transcription in neoplastic cells of lymphoma cases and cell
lines otherwise classified as EBV negative by conventional
Fig. 3 Sensitive In situ detection of EBV by RNAscope analysis in
cHL cell lines. Single dots of EBNA1 mRNA were detected in rare
lymphoma cells (pointed by the arrow) of 4 conventional EBV-
negative cell lines scoring positive on ddPCR analysis for EBNA1
(L1236, UHO1, SUP-HD1, HDLM2), but in no cells of 2 conventional
EBV-negative cell lines lacking EBNA1 signal on ddPCR (KMH2,
L428). In contrast, conventional EBV-positive cHL cell lines used as
positive controls (L591, AM-HLH) showed a higher number of
RNAscope dots per cell in most cells.
Fig. 2 Sensitive In situ detection of EBV by RNAscope analysis in
lymphoma biopsies. (A, E, I) BL; (B, F, J) DLBCL; (C, G, K) cHL;
(D, H, L) FL. A red punctuate staining produced by EBNA1 mRNA
molecules is detected in neoplastic cells, often at the nuclear periphery.
Single red dots were detected in occasional lymphoma cells of EBER-
negative cases positive for EBNA1 at qPCR (a–d), compared with
often multiple intracellular dots in most lymphoma cells of EBER-
positive controls (e–h), and to no signal whatsoever in lymphoma cells
of cases negative at both EBER-ISH and EBNA1-qPCR (i–k). Ori-
ginal magnification: 25×. Insets in A-D show single EBNA1-positive
lymphoma cells (magnified in a or undergoing mitosis in b).
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methods. We also tried to microdissect such rare lymphoma
cells positive for EBNA1 at RNAscope in order to further
confirm their belonging to the neoplastic clone through the
identification of the same immunoblobulin gene rearrange-
ment; however, this turned out to be not technically feasible
as the often single RNAscope signal observed in the rare
positive cells under the optimal optical conditions of a
diagnostic microscope was impossible to clearly appreciate
at the inverted LCM microscope in tissue sections without
coverslip (as required by the microdissection procedure).
We then studied four additional interesting B-cell lym-
phoma cases: one DLBCL, characterized by an area of
strongly EBER-positive cells separated from another com-
pletely negative (Fig. 4a–e); one DLBCL, originally EBER-
positive but relapsed 2 years after therapy as EBER-negative
(Fig. 4f–j); one cHL, initially EBER-positive and then
evolved to an EBER-negative lymphoma with features
intermediate between DLBCL and cHL (Fig. 5a–e) 1 year
after therapy; and one EBER-positive cHL that relapsed 3
years after therapy as EBER-negative (Fig. 5f–j). We,
therefore, show that EBV loss at relapse, which had been
already documented in cHL [35, 36], can occur also in
DLBCL. We next looked for potential EBV vestiges in the
three relapse biopsies and in the EBER-negative area of the
otherwise EBER-positive DLBCL biopsy, by performing
RNAscope for EBNA1. We indeed observed in all four
cases single red dots in scattered tumor cells in the relapse
biopsies or in the EBER-negative area (Figs. 4, 5) compared
with often multiple red signals in most tumor cells of the
matched onset biopsies and of the EBER-positive area,
respectively (not shown). We also confirmed the clonal
relation between the onset and relapse samples, as well as
between the EBER-positive and EBER- negative areas of the
same DLBCL biopsy, by fragment length analysis of the
immunoglobulin heavy chain variable gene rearrangement
following microdissection of ~1500–2000 single HRS cells
and of groups of ~40–50 non-Hodgkin lymphoma cells from
hematoxylin/eosin-stained sections (Figs. 4, 5).
Finally, we addressed whether or not the weak
EBNA1 signal observed on RNAscope in rare tumor cells
of conventional EBV-positive lymphomas could be due to
secondary infection by a bystander EBV-infected cell
Fig. 4 RNAscope and clonality analyses of a DLBCL case showing
distinct tumor areas with discordant EBV status (a–e) and an
EBV-positive DLBCL case relapsed as EBV-negative by conven-
tional methods (f–j). DLBCL case characterized by an area of
strongly EBER-ISH positive cells (a) and a region of completely
negative EBER-ISH cells (b) that however showed occasional EBNA1
mRNA signals by RNAscope (red chromogen pointed by the arrow;
panel c). An identically sized clonal immunoglobulin heavy chain
variable gene rearrangement (260 base pairs) was identified in both the
EBER-positive (d) and EBER-negative (e) microdissected areas.
DLBCL case initially EBER-positive (brown chromogen; f) and
relapsed as negative by EBER-ISH (g) while showing rare EBNA1
mRN signals by RNAscope (red chromogen; arrows in h). An iden-
tically sized abnormal clonal immunoglobulin heavy chain variable
gene rearrangement (692 base pairs) was identified in both the EBER-
positive (i) and EBER-negative (j) biopsies after microdissection of
tumor cells.
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undergoing viral lytic replication. To do so, we investigated
In situ the expression pattern that EBNA1 displays in nor-
mal latently EBV-infected lymphoid cells that are occa-
sionally detected by EBER-ISH staining in reactive lymph
nodes or in the reactive component of lymphoma tissues
(especially cHL). In 2 such biopsies with readily detectable
EBER-positive reactive lymphocytes (n= 1 reactive lym-
phadenitits; n= 1 cHL—Supplementary Fig. 2), RNAscope
for EBNA1 consistently produced an intense staining
(homogeneous or comprising multiple dots) in small reac-
tive lymphoid cells (presumably in EBV latency I, i.e.,
expressing not only EBER but also EBNA1 [5, 6, 37]) or in
activated germinal center B cells (presumably in latency II,
i.e., expressing not only EBER and EBNA1 but also LMP1
[38]. This strong staining pattern resembled that of tumor
cells in EBER-positive lymphomas much more than the
weak staining (often consisting of a single dot) observed in
rare tumor cells of EBER-negative cases and lines scoring
positive at qPCR/dPCR for EBNA1 (Figs. 2–5). Because
such intense EBNA1 staining likely typifies EBV infection
(in its various latent forms) of both normal and tumor
lymphoid cells, secondary EBV infection of rare tumor cells
within an originally EBV-negative lymphoma clone is
unlikely to explain the EBNA1 expression pattern actually
shown by those rare lymphoma cells, reinforcing the alter-
native explanation of an originally clonal EBV infection
followed by progressive loss of the viral genome from most
tumor cells and persisting traces of it in only a few.
Altogether, these findings further support the hypothesis
that even if the lymphoma clone can largely loose the EBV
genome over time, its traces can still be detected by high-
sensitivity methods.
EBV-encoded microRNAs expression by qPCR and
droplet digital PCR
Based on our previous findings in BL [19], as an additional
validation we analysed the expression of three
EBV-encoded miRNAs, namely EBV-miR-BART9-5p,
EBV-miR-BART10-3p, and EBV- miR-BART19-3p in
Fig. 5 RNAscope and clonality analyses of an EBV-positive cHL
case relapsed as EBV-negative by conventional methods (a–e) and
an EBV-positive cHL case evolved to a lymphoma intermediate
between cHL and DLBCL EBV-negative by conventional methods
(f–j). Clonal EBV infection was detected by EBER-ISH in the onset
biopsy of a cHL case (blue chromogen; a). Conversely, EBER-ISH
staining resulted negative in the relapse biopsy post-therapy (b).
However, occasional red dots indicating EBNA1 mRNA were
observed in rare tumor cells of the relapse biopsies (panel c). An
identically sized clonal immunoglobulin heavy chain variable gene
rearrangement (266 base pairs) was identified in HRS cells micro-
dissected from both the initial (panel d) and the relapse (e) biopsies.
EBER-ISH positive cHL (blue chromogen; f) evolved in EBER-ISH-
negative lymphoma with features intermediate between cHL and
DLBCL (g). Occasional red dots indicating EBNA1 mRNA were
observed in rare tumor cells of the relapse biopsies (h). An identically
sized clonal immunoglobulin heavy chain variable gene rearrangement
(262 base pairs) was identified in whole-tissue sections from both the
initial (i) and the relapse (j) biopsies.
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non-Hodgkin lymphoma cells microdissected from EBER-
stained tissue sections. EBER-positive samples showed a
clear expression of viral miRNAs, but also most of the
tested EBER-negative cases that were positive at DNA
qPCR for EBNA1 presented some degree of expression of
at least one EBV-encoded miRNA in all technical triplicates
performed (6/9 BL, 7/11 DLBCL, 1/3 FL) (Fig. 6 and
Supplementary Table 1).
By ddPCR we further confirmed, in all cases classified as
EBER-negative but resulted qPCR-positive for miRNAs,
the presence of viral miRNA copies ranging from 1 to 9%
of conventional EBV-positive lymphomas (Supplementary
Table 1). Conversely, no ddPCR signals were ever detected
in any technical triplicate of any tested EBER-negative
lymphoma (19 DLBCL, 44 FL) that were negative at qPCR
for EBV miRNAs.
Exome-wide somatic mutation load in relation to
EBV status
In a previous whole-exome sequencing study of tumor and
normal cells microdissected from cHL biopsies, the load of
total somatic mutations (whether nonsynonymous or silent/
non-coding) that were present in a major tumor clone was
much lower in EBER-positive lymphoma cells (n= 4 cases;
median 0 mutations, range 0–64) than in EBER-negative
ones (n= 30 cases; median 118 mutations, range 0–665;
p value < 0.01) [27], suggesting that persistent viral gene
expression during lymphomagenesis may relieve the pres-
sure toward selection of exome-wide mutagenic mechan-
isms. Tumor cells of 16/30 EBER-negative cHL cases
previously studied [27] could be assessed by qPCR for EBV
genes in the present study, with 11 turning out to be
negative and 5 positive (Supplementary Table 1). Interest-
ingly, the somatic mutation load of the EBER- negative/
qPCR-positive subset appeared relatively similar to EBER-
negative cases, with 3/5 cases showing a conspicuous
number of mutations (Fig. 7); these 3 cases all carried
specific gene mutations (respectively in STAT3, SOCS1,
TP53; in MYD88; and in CD95/FAS) that activate signaling
pathways (JAK-STAT and NF-kB) or inactivate cellular
processes (apoptosis) known to be respectively induced and
evaded by EBV in cHL [27].
Methylation assay findings
The promoter region of some tumor-suppressor genes,
including CDH1 and MGMT, has been shown to become
hyper-methylated during EBV-induced primary B-cell
transformation [23, 24]. Therefore, considering that these
heritable alterations could be maintained also after the loss
of the virus, we investigated the methylation pattern of the
CDH1 and MGMT gene promoters in whole lymphoma
Fig. 6 Expression of EBV-encoded miRNAs in EBER-negative
cases by RT-qPCR. Expression values (2−Δct) are reported on the
y-axis, indicating low-level viral miRNAs expression in several
samples classified as EBER-negative (red bars), compared with higher
expression in all EBER-positive cases (blue bars).
Fig. 7 Exome-wide somatic mutation load in relation to EBV sta-
tus. Load of total somatic mutations (mean ± SD as error bar) present
in a major lymphoma clone of cHL cases (circles) EBER-positive (n=
4, denoted as EBV-positive), EBER-negative/qPCR-negative (n= 11,
denoted as EBV-negative qPCR-negative) and EBER-negative/qPCR-
positive (n= 5, denoted as EBV-negative qPCR-positive). The same
result was obtained when considering only somatic nonsynonymous
mutations (not shown).
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tissue sections. We compared the methylation status of the
17 EBER-positive cases (10 BL, 4 DLBCL, 3 FL) to that
observed in cases classified as EBER-negative but in which
we detected the presence of the virus by DNA qPCR (n=
20; 6 BL, 8 DLBCL, 6 FL). Interestingly, the methylation
status of these two groups was quite similar (28 and 23%
respectively for MGMT; 58 and 63% respectively for
CDH1) (Fig. 8). In contrast, EBER- negative/qPCR-nega-
tive cases (n= 20; 10 DLBCL, 10 FL) showed a lower level
of promoter methylation in comparison to both EBER-
positive cases and EBER-negative/qPCR-positive cases
(Fig. 8).
Discussion
Epstein–Barr virus plays a pathogenetic role in several
lymphoid and epithelial malignancies [2, 39, 40], and the
methods generally used to determine EBV status of a cancer
are represented by in-situ hybridization for EBER and
immunohistochemistry for LMP1 or EBNA1. By these
techniques, the proportion of cases clonally infected by
EBV is >95% in endemic BL, 10–30% in sporadic BL and
cHL of western countries, and 1–10% in DLBCL. Whereas
the pathogenetic link with EBV is easy to conceive in tumor
cases clonally expressing one or more viral products, it has
been proposed that the virus might be implicated also in
virus-negative tumors through a “hit-and-run” mechanism.
This theory postulates that the transforming events
initially provided by the virus are later functionally replaced
by stable (epi)genetic changes of the host cell. Then, the
viral episomal genome, whose propagation during cell
proliferation is intrinsically imperfect, may be progressively
lost from the tumor clone as it does not provide anymore a
fitness advantage, and can actually be even counter-
productive being a potential target of the host immune
response [13, 14, 19].
Although conventional EBV-positive BL (whether
endemic or sporadic) and cHL do harbor fewer driver gene
mutations compared with their EBV-negative counterparts
[27, 41], the hypothesis of “hit- and-run” oncogenesis is
difficult to formally proof. The previous few historical
attempts to directly address it in primary cases of EBV-
associated lymphomas (BL [42] and cHL [43–45]) led to
controversial results. This is particularly the case for cHL
where a further major technical challenge is represented by
the rarity of tumor cells (typically <5%) in the involved
tissue and where opposite results were reported in pediatric
[43] versus adult [44, 45] series, respectively supporting
and refuting the “hit-and-run” hypothesis. More recently,
by adopting a methodological strategy combining optimal
sensitivity (qPCR for EBV nucleic acids on pure lymphoma
cell populations isolated through microdissection of con-
ventional EBV-negative sporadic BL biopsies) and high
specificity (EBER staining of tissue sections to avoid co-
microdissection of even a single normal EBER-positive
cell), we observed traces of EBV infection in 6/6 of con-
ventional EBV-negative BL [19].
In the present study, we analysed a larger and more
comprehensive series of typical EBV-associated lympho-
mas, including DLBCL and adult cHL in addition to BL.
This was performed by applying several methodological
approaches rigorously guarded not only against technical
artifacts by means of several water controls, but also against
false positives of non-technical origin by means of biolo-
gical controls consisting of several EBV-unrelated neo-
plasms (20 HCL, 10 T-LL, and 10 MCL). All these
quantitative analyses documented the consistence presence
at a low level of one or more of the 5 EBV nucleic acids
tested (DNA of BamHI-W and EBNA1; and the miRNAs
BART8- 5p, BART10-3p, and BART19-3p) in tumor cells
of several B-cell lymphomas classified as EBV-negative by
routine methods; these included 37% (11/30) DLBCL, 50%
(16/32) cHL and, strikingly, 80% BL (12/15 cases,
Fig. 8 Methylation assay
findings. The methylation level
of MGMT and CDH1 promoter
in 17 non-Hodgkin lymphoma
EBER-positive cases overlapped
that detected in 20 EBER-
negative/qPCR-positive cases,
whereas it was higher than
observed in EBER-negative/
qPCR-negative cases (n= 20).
P values were calculated
according to T-test.
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considering also those previously reported in [19]). This
proportion was considerably lower in FL (6%; 3/47 cases),
for which the pathogenetic link with EBV is more elusive as
only 2.6% of FL cases have been reported to be EBV-
positive by standard methods [20]. In contrast, none of the
40 biological negative controls showed any positive signal
for the EBV nucleic acids tested (BamHI-W and EBNA1).
Moreover, although it can be theoretically hypothesized that
the qPCR signal detected in EBER-negative DLBCL, BL
and FL cases might have originated from the co-
microdissection of a few normal occult EBER-positive
cells even if extreme care was taken to isolate areas of
tumor cells completely devoid of any EBER staining, the
same argument is not likely to hold for cHL cases, where
the normal cells surrounding the single microdissected HRS
cells (and thus potentially contaminating the microdissec-
tion procedure) are known to be mostly T cells not infected
by EBV. Another argument against contamination is the
fact that, among EBER-negative cases, the highest fre-
quency of EBV-positivity at qPCR was observed in BL
despite this being the lymphoma entity with the lowest non-
tumor content in tissue biopsies.
Most importantly, by using the highly sensitive RNA-
scope analysis, a ISH technology enabling single-molecule
detection and preservation of tissue morphology, we
orthogonally validated In situ the presence of EBNA1
mRNA in occasional morphologically neoplastic cells of
lymphoma cases otherwise classified as EBV negative by
conventional methods, at an expression level likely lower
(often a single red dot per cell) than conventional EBV-
infected tumor cells (often showing multiple red dots
per cell).
Although it was technically impossible to microdissect
these rare lymphoma cells EBV-positive only at RNAscope
for further proving by immunoglobulin gene sequencing the
clonal relationship with their EBV-negative counterparts,
we note that the morphology of such cells was always
neoplastic both in the non-Hodgkin lymphoma cases
(medium to large size, more cytoplasm, finer chromatin
with a nucleolus often present) and in cHL (typical HRS
cell morphology). Therefore, although normal EBV-
infected cells can assume diverse morphologies (including
activated ones, such as immunoblastic or HRS-cell like) in
addition to the more frequent one of a resting lymphocyte,
the fact that none of the cells EBV-positive only at RNA-
scope ever displayed the morphology of a resting lympho-
cyte, and that they all displayed a stereotypical tumoral
morphology instead, argues against the normal nature of
these RNAscope-positive cells. Finally, the neoplastic nat-
ure of those primary cells weakly expressing EBNA1 was
corroborated by ddPCR and RNAscope analyses formally
demonstrating, in unequivocal tumor cells of conventional
EBV-negative cHL and BL cell lines, the presence and
expression of EBV genes with a pattern resembling that of
conventional EBV-negative primary lymphomas positive at
qPCR, ddPCR, and RNAscope.
Traces of the previously clonal EBV infection were also
detected by RNAscope in scattered tumor cells of 4 B-cell
lymphoma cases (1 DLBCL and 2 cHL) that relapsed as
EBER- ISH negative while being positive at disease onset,
as well as in an EBER-negative area separated, within the
same DLBCL biopsy, from an EBER-positive area;
immunoglobulin rearrangement analysis confirmed a clonal
relation between the lymphoma at onset (EBER-positive)
and relapse (EBER-negative), as well as between the two
distinct area of the same DLBCL biopsy. Therefore,
although we cannot formally exclude that the RNAscope
signal occasionally detected in the other EBER-negative
lymphomas we analyzed (Supplementary Table 1 and
Fig. 1) may result from secondary EBV infection of rare
lymphoma cells, the above described DLBCL and cHL
cases losing EBV at relapse (or losing it even in the same
biopsy), support loss of the viral genome from a tumor that
initially was clonally infected as a plausible origin also of
the RNAscope signal seen in the other EBER-negative
lymphomas analyzed. We also note that this RNAscope
staining often consisted in a single dot per cell in contrast to
the more abundant EBNA1 labeling of clonally infected
EBER-positive lymphoma cells and of normal lymphoid
cells latently infected by EBV that can be occasionally
observed in tissue biopsies. Such a different staining pattern
is an additional argument pointing to loss of viral genomes
as a more likely scenario than secondary EBV infection of
rare tumor cells, as the latter should result in a higher
intracellular viral genome load like that we observed in the
context of primary infection of normal or neoplastic B cells.
Loss of the EBV genome may therefore also explain the
significant minority of EBV-infected B-cell lymphoma
cases showing EBER positivity in only a fraction of cells
(10/27 cases in [53, 54]).
Progressive loss of viral episomes after cellular divisions
[14, 46] within a lymphoma clone that in origin was clon-
ally infected is a plausible mechanism underlying the results
we observed in EBER-negative lymphomas showing traces
of EBV infection. However, we cannot exclude, especially
in cell lines continuously growing in vitro since decades,
that the RNAscope signal seen in rare tumor cells of EBER-
negative lymphomas is contributed by viral DNA integra-
tion into the cellular genome; indeed, evidences suggest that
the EBV genome can randomly integrate at vulnerable sites
of the cellular genome resulting in host genome instability
or deregulated gene expression [47–52].
The results obtained with these analyses directly asses-
sing the presence of the virus in conventional EBV-negative
primary tumors and cell lines suggest that EBV infection
might have happened in the early pathogenesis of a
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significantly greater proportion of B-cell lymphoma cases
than commonly thought, in keeping with the “hit-and-run”
hypothesis. Furthermore, indirect correlative analyses on
genetic and epigenetic changes potentially associated to
EBV infection are also compatible with the “hit-and-run”
hypothesis. Indeed, the exome-wide somatic mutation bur-
den was low in conventional EBV-positive cHL cases,
while being higher in conventional EBV-negative cases and
relatively similar in the group with traces of EBV infection
and in the group without. However, we acknowledge the
limited size of the group of lymphoma cases with traces of
EBV infection and with available whole-exome sequencing
data, such that these preliminary findings need confirmation
in a larger case series.
Likewise, at the epigenetic level, the CHD1 and MGMT
gene promoters (which become hypermethylated during
EBV-induced primary B-cell transformation) [22–26]
exhibited, in lymphoma cases of diverse histologies (BL,
DLBCL, and FL) harboring only traces of EBV infection, a
considerable level of methylation that was similar to that
observed in conventional EBV-positive cases and greater
than in cases not featuring any traces of EBV infection,
These findings extend to, and refine within, B-cell lym-
phomas the association between EBV infection and CDH1/
MGMT promoter methylation previously described in epi-
thelial cancers [25].
Our results do not affect the diagnostic work-up as
conventional EBV-positive lymphomas should still be
diagnosed accordingly to the current WHO criteria [11];
however, whether lymphoma cases showing only traces of
EBV infection have some specific biological and/or clinical
features may warrant further study. Also, although in our
relatively small series of adult BL the majority of EBER-
negative cases showed traces of EBV infection (this paper
and ref. [19]), we are aware that BL often develops in EBV-
seronegative children presumably not yet infected by EBV
[55] and we do not claim that Burkitt lymphomagenesis
requires EBV infection of tumor cells in each and every
pediatric or adult case.
In conclusion, collectively, our findings expand the
spectrum of B-cell lymphoma cases potentially linked with
EBV infection and may support the efforts toward the
design and development of prophylactic vaccination stra-
tegies against this virus for reducing the burden of EBV-
associated disease worldwide [56].
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